Predictive performance of population pharmacokinetic models in InsightRX ® for model‐informed precision dosing for Cefepime
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2025
DOI: 10.1002/phar.70029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2025. Verfasst von Christina König und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: Cefepime, Anti-Bacterial Agents, Models, Biological, Cephalosporins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: InsightRx.
Abstract (Originalsprache)
Background
Model‐informed precision dosing (MIPD) is a promising tool used to ensure therapeutic antimicrobial concentrations. Model selection and sampling strategy might lead to different pharmacokinetic (PK) parameter estimates. Herein, we assess the predictive performance for cefepime PK in two models implemented within the InsightRX software using differing sampling approaches.
Methods
Historic cefepime PK data and individual Bayesian estimates in predominantly critically ill patients, some of whom had extracorporeal support, served as the reference standard. Two population PK models (A; B) were evaluated using four sampling scenarios: (i) trough only, (ii) midpoint only, (iii) trough + midpoint, and (iv) peak + midpoint + trough. The median prediction error (MPE) and median absolute prediction error (MAPE) were calculated for clearance (CL) and volume of central compartment (V c ). Predicted categorical achievement of ≥70% time that the free drug concentration was greater than the minimum inhibitory concentration [ f T>MIC (8/16mg/L) ] was compared.
Results
MAPE and MPE for CL and V c resulted in variability that was dependent on model and sampling strategy. Both models' overall MPE and MAPE for CL were 30% for the majority of test scenarios across both models, respectively. When excluding patients with extracorporeal support, MPE/MAPE for V c decreased to 3.7–4.8/23.3%–34.5% and −7.9–2.5/25.2%–29.6% for model A and B, respectively. Using each model and sampling scheme, only four patients had discordant predicted achievement of ≥70% f T>MIC (8/16mg/L) .
Conclusions
These two population PK models and all sampling scenarios demonstrated acceptable prediction of cefepime PK parameters and pharmacodynamic exposures; therefore, they demonstrated suitability for utilizing MIPD for cefepime therapeutic drug monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.
- Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
ORCID-Profile: Joseph L Kuti, Andrew J Fratoni
Förderung
- InsightRx
Zitieren
APA
König, C., Kuti, J. L., & Fratoni, A. J. (2025). Predictive performance of population pharmacokinetic models in InsightRX ® for model‐informed precision dosing for Cefepime. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.70029
Vancouver
König C, Kuti JL, Fratoni AJ. Predictive performance of population pharmacokinetic models in InsightRX ® for model‐informed precision dosing for Cefepime. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2025. doi:10.1002/phar.70029
BibTeX
@article{Knig2025,
author = {König, Christina and Kuti, Joseph L and Fratoni, Andrew J},
title = {Predictive performance of population pharmacokinetic models in InsightRX ® for model‐informed precision dosing for Cefepime},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2025},
doi = {10.1002/phar.70029}
}
EUVIMED